Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA.
Semin Oncol. 2013 Jun;40(3):361-74. doi: 10.1053/j.seminoncol.2013.04.015.
First-line therapy for men with metastatic or recurrent prostate cancer following definitive local therapy is medical or surgical castration. Though effective initially in most patients, the majority of tumors develop castration resistance, necessitating the addition of further therapy. The historic treatment paradigm of second-line androgen manipulation, followed by cytotoxic salvage chemotherapy, has changed in recent years with better understanding of mechanisms that lead to castration resistance. This review will outline the data supporting the use of targeted and chemotherapeutic agents for prostate cancer, review data leading to US Food and Drug Administration (FDA) approval of the newest agents abiraterone, enzalutamide, and cabazitaxel, as well as review ongoing studies of novel agents.
对于接受根治性局部治疗后发生转移或复发的前列腺癌男性患者，一线治疗方法是采用医学或手术去势。虽然这种方法起初对大多数患者有效，但大多数肿瘤会产生去势抵抗，需要添加进一步的治疗。近年来，随着对导致去势抵抗机制的深入了解，二线雄激素治疗加细胞毒性解救化疗的历史治疗模式已经发生了改变。本文将概述支持使用靶向和化疗药物治疗前列腺癌的相关数据，回顾导致美国食品和药物管理局（FDA）批准阿比特龙、恩杂鲁胺和卡巴他赛这三种最新药物的相关数据，并综述新型药物的研究进展。
